The European Commission (EC) has granted a licence for the use of ocrelizumab, also known as Ocrevus, in people with primary progressive multiple sclerosis (PPMS) and relapsing remitting multiple...
Our news web pages include ground-breaking multiple sclerosis news and research from around the world.
These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.
Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.
We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years.
The European Commission (EC) has granted a licence for the use of ocrelizumab, also known as Ocrevus, in people with primary progressive multiple sclerosis (PPMS) and relapsing remitting multiple...
Back in July 2017, the Medical and Healthcare products Regulatory Agency (MHRA) highlighted restrictions on the use of daclizumab (Zinbryta) for relapsing remitting multiple sclerosis (RRMS)...
Scientists have conducted a study that looks at how traditional initial disease modifying treatment (DMT) choices, including dimethyl fumarate, fingolimod, or natalizumab compare with rituximab in...
The regeneration of intact myelin sheaths is a necessary prerequisite for patients to recover from multiple sclerosis (MS) relapses. Nevertheless, the body's ability to regenerate myelin decreases...
The McDonald Criteria, used for the diagnosis of multiple sclerosis (MS), has been revised by a 30-member international panel of MS experts co-chaired by Jeffrey Cohen, MD (Cleveland Clinic) and...
The Department of Health has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using beta interferons and glatiramer acetate for the treatment of multiple...
Medday, the makers of Biotin have formally withdrawn their application for EMA (European Medicines Agency) marketing authorisation for progressive MS drug Qizenday.
Qizenday is a capsule...
Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for fingolimod for the treatment of children and adolescents 10 years of age or...
A study of around 7,000 people with MS in North America has assessed how diet quality is associated with disability.
Researchers at John Hopkins School of Medicine used the NARCOMS (North...
Insights into how the body clock and time of day influence immune responses have been revealed in a study published in the journal...